Lertsinudom Sunee, Sawanyawisuth Kittisak, Srisoi Sutasinee, Areemit Jringjai, Hansuri Nadthatida, Tawinkan Nirachra, Theeranut Ampornpan, Sripanidkulchai Bangorn, Pranboon Sineenard
Faculty of Pharmaceutical Science, Khon Kaen University, Khon Kaen, Thailand.
Research and Training Center for Enhancing Quality of Life Working-Age People, Faculty of Nursing, Khon Kaen University, Thailand.
J Tradit Complement Med. 2019 Oct 15;11(2):90-94. doi: 10.1016/j.jtcme.2019.09.006. eCollection 2021 Mar.
(VC) is a herb that can alleviate nicotine addiction, potentially aiding in smoking cessation. Previous studies have examined four-to eight-week treatments using VC, but have found it to be ineffective. This study aimed to evaluate the smoking cessation effects of VC in addicted smokers over a longer treatment duration with pastilles.
This was a randomized double-blinded controlled trial conducted at a community pharmacy. The inclusion criteria were age between 18 and 60 years, intention to quit smoking, and low to moderate level of nicotine addiction. All eligible participants were stratified according to nicotine addiction level and then randomly assigned either VC treatment or placebo. The VC group received two pastilles three times daily, while the control group received a placebo for 12 weeks. The outcomes were continuous abstinence rate (CAR) and point abstinence rate (PAR) at four and 12 weeks.
There were 121 eligible participants; 10 participants were not willing to participate. In total, there were 111 eligible participants, 54 of whom were treated with VC (48.65%) and 57 of whom were given a placebo (51.35%). Baseline characteristics were comparable between the two groups. The VC group had a significantly higher chance of smoking cessation at 2.01 (95% CI of 1.03, 3.92) compared with the placebo group at the end of the study. There were no significant side effects in either group.
The VC pastille group had significantly higher CAR than the placebo group at week 12.
VC是一种可减轻尼古丁成瘾、可能有助于戒烟的草药。既往研究对使用VC进行四至八周的治疗进行了考察，但发现其无效。本研究旨在评估在更长治疗疗程中使用含片形式的VC对成瘾吸烟者的戒烟效果。
这是一项在社区药房进行的随机双盲对照试验。纳入标准为年龄在18至60岁之间、有戒烟意愿且尼古丁成瘾程度为低至中度。所有符合条件的参与者根据尼古丁成瘾水平进行分层，然后随机分配接受VC治疗或安慰剂。VC组每天服用三次两片含片，而对照组接受12周的安慰剂治疗。观察指标为4周和12周时的持续戒烟率（CAR）和点戒烟率（PAR）。
有121名符合条件的参与者；10名参与者不愿参加。总共111名符合条件的参与者，其中54名接受VC治疗（48.65%），57名接受安慰剂治疗（51.35%）。两组的基线特征具有可比性。在研究结束时，与安慰剂组相比，VC组的戒烟几率显著更高，为2.01（95%置信区间为1.03，3.92）。两组均无显著副作用。
在第12周时，VC含片组的CAR显著高于安慰剂组。
